sellWeak cluster of 210b5-1 plan
Hopkinson Craig C. sold $12M of ALKS
EVP R&D, Chief Medical Officer at Alkermes plc.. 349,340 shares at an average of $33.92, traded Feb 12, 2025, filed Feb 14, 2025.
Warning score
33Value
$12M
349,340 shares
Holdings after
57,875
-133% from before
From 52-week low
+30%
low $25.70, close $33.50
From 52-week high
0%
high $33.50, as of Feb 12, 2025
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price, last year
Rows in this filing
Every transaction in Form 4 0001127602-25-004948, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 12, 2025 | MOption exercise Ordinary Shares10b5-1 | +87,566 | $20.03 | $1.8M | 151,166 | Feb 14, 2025 |
| Feb 12, 2025 | MOption exercise Ordinary Shares10b5-1 | +111,630 | $19.34 | $2.2M | 262,796 | Feb 14, 2025 |
| Feb 12, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -171,813 | $32.69 | $5.6M | 90,983 | Feb 14, 2025 |
| Feb 12, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -33,108 | $33.27 | $1.1M | 57,875 | Feb 14, 2025 |
| Feb 13, 2025 | MOption exercise Ordinary Shares10b5-1 | +108,833 | $31.93 | $3.5M | 166,708 | Feb 14, 2025 |
| Feb 13, 2025 | MOption exercise Ordinary Shares10b5-1 | +35,586 | $24.59 | $875k | 202,294 | Feb 14, 2025 |
| Feb 13, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -35,586 | $34.02 | $1.2M | 166,708 | Feb 14, 2025 |
| Feb 13, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -108,833 | $36.02 | $3.9M | 57,875 | Feb 14, 2025 |
| Feb 12, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -87,566 | $0.00 | $0 | 0 | Feb 14, 2025 |
| Feb 12, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -111,630 | $0.00 | $0 | 50,104 | Feb 14, 2025 |
| Feb 13, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -108,833 | $0.00 | $0 | 0 | Feb 14, 2025 |
| Feb 13, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -35,586 | $0.00 | $0 | 71,172 | Feb 14, 2025 |
Related signals
Other insiders at Alkermes plc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 0Weak | sell10b5-1 | ALKS Alkermes plc. | Parisi Samuel Joseph VP, Finance (Interim PAO) | $66k | 1,938 | |
| 9Weak | sell 210b5-1 | ALKS Alkermes plc. | Parisi Samuel Joseph VP, Finance (Interim PAO) | $132k | 3,743 | |
| 0Weak | sell 210b5-1 | ALKS Alkermes plc. | Parisi Samuel Joseph VP, Finance (Interim PAO) | $47k | 1,327 | |
| 25Weak | sell10b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $3.2M | 100,918 | |
| 9Weak | sell 310b5-1 | ALKS Alkermes plc. | LAURENCIN CATO T director | $86k | 2,691 | |
| 40Moderate | sell 310b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $2.0M | 61,151 | |
| 29Weak | sell 310b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $290k | 9,221 | |
| 32Weak | sell 310b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $442k | 14,349 | |
| 21Weak | sell 310b5-1 | ALKS Alkermes plc. | Nichols Christian Todd SVP, Chief Commercial Officer | $152k | 5,208 | |
| 15Weak | sell10b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $1.8M | 58,996 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.